m6A-centered Drug Response Information
General Information of the Drug (ID: M6APDG01376)
Name |
CPL-7075
|
||||
---|---|---|---|---|---|
Synonyms |
Ajulemic acid; Lenabasum; IP-751; CT-3; 137945-48-3; IP 751; UNII-OGN7X90BT8; CPL7075; JBT-101; OGN7X90BT8; Resunab; (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid; (6ar,10ar)-3-(1,1-Dimethylheptyl)-1-Hydroxy-6,6-Dimethyl-6a,7,10,10a-Tetrahydro-6h-Benzo[c]chromene-9-Carboxylic Acid; DMH-THC-11-OIC; AB-III-56; CT 3; CPL 7075; Lenabasum [USAN]; HU-239; AC1MJ0SY; SCHEMBL26441; CHEMBL456341; GTPL9772; IP751; Mixed CB agonist/sodim channel blocker (pain), Cervelo
Click to Show/Hide
|
||||
Status |
Phase 3
|
||||
Structure |
|
||||
Formula |
C25H36O4
|
||||
InChI |
1S/C25H36O4/c1-6-7-8-9-12-24(2,3)17-14-20(26)22-18-13-16(23(27)28)10-11-19(18)25(4,5)29-21(22)15-17/h10,14-15,18-19,26H,6-9,11-13H2,1-5H3,(H,27,28)/t18-,19-/m1/s1
|
||||
InChIKey |
YCHYFHOSGQABSW-RTBURBONSA-N
|
||||
PubChem CID | |||||
TTD Drug ID |
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Tumor necrosis factor (TNF)
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CPL-7075. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of CPL-7075 through regulating the expression of Tumor necrosis factor (TNF). | [1], [2] | ||
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CPL-7075. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CPL-7075 through regulating the expression of Tumor necrosis factor (TNF). | [2], [3] | ||
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CPL-7075. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CPL-7075 through regulating the expression of Tumor necrosis factor (TNF). | [2], [4] | ||
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CPL-7075. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CPL-7075 through regulating the expression of Tumor necrosis factor (TNF). | [2], [4] | ||
YTH domain-containing family protein 3 (YTHDF3)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CPL-7075. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of CPL-7075 through regulating the expression of Tumor necrosis factor (TNF). | [1], [2] | ||
References